



## QUANTEL MEDICAL COMPLETES ACQUISITION OF ELLEX

**Cournon-d’Auvergne, France – 30 June 2020** – Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT® and iTrack®), via the financial holding company Lumibird Medical.

The purchase includes the Ellex brand name, its R&D and production site based in Adelaide and its subsidiaries based in Australia, Japan, the United States, France and Germany.

The coming together of these two companies—both renowned in the field of ophthalmology—represents a real milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.

The coming together of Quantel Medical and Ellex offers huge potential for growth and value creation through various synergies, including the sharing of R&D capacity and production sites, and the strengthening of their clinical work to meet the current and future needs of ophthalmologists.

Quantel Medical and Ellex have complementary strengths, in particular their product positioning, experience and knowledge of the ophthalmology market. Bringing together the product portfolios of both companies will enable them to better meet the needs of healthcare professionals, in terms of both the applications and positioning of their ranges.

*“Ellex’s strong, direct positioning in certain markets, combined with the strength of Quantel Medical’s international distribution network will enable our two companies to effectively combine their presence on the global market,” explains Keith Byrne, Vice President of Ellex. “This means we can respond to the requirements and infrastructure of existing customers as well as exploring new markets.”*

*Jean-Marc Gendre, CEO Quantel Medical and Deputy CEO Lumibird Group, adds: “Our goal is clear: to become the global leader in ophthalmic laser and ultrasound solutions for the diagnosis and treatment of eye diseases.”*



### **About Quantel Medical**

With over 25 years of knowledge and experience in the field of ophthalmic lasers, Quantel Medical provides ophthalmologists with therapeutic laser solutions to treat the four major causes of blindness: glaucoma, cataracts, diabetic retinopathy and macular degeneration. Its products are available for direct purchase in France, the United States, Poland and Slovenia, and via 100 independent distributors in over 110 countries.

Quantel Medical is a subsidiary of Lumibird, a global leader in the development of solid-state lasers for scientific and industrial use.

### **About Lumibird**

Lumibird is one of the world's biggest laser specialists. Drawing on fifty years of experience and expertise in solid-state laser, laser diode and fibre laser technologies, the Group designs, manufactures and distributes high-performance lasers for scientific use (research laboratories, universities), industrial use (manufacturing, defence/space, LiDAR sensors) and medical use (ophthalmology). Formed through the merger of the Keopsys and Quantel groups in October 2017, Lumibird boasts over 580 employees and a turnover of more than €110 million. It has a presence in Europe, America and Asia.

Lumibird Group shares are listed in Compartment B of Euronext Paris. FR0000038242 – LBIRD.

### **About Ellex**

Ellex designs, develops, manufactures and sells innovative products that enable ophthalmic surgeons the world over to effectively treat eye diseases. Based in Adelaide, Australia, the company is the world leader in this field. The Ellex product range comprises lasers and ophthalmic devices for the treatment of glaucoma, retinal diseases caused primarily by diabetes, secondary cataracts, vitreous opacities and age-related macular degeneration. Its production sites are located in Adelaide, Australia, and Fremont, California. Ellex offers direct sales and service support to ophthalmic surgeons through subsidiaries in Minneapolis, Lyon, Berlin and Tokyo. Other markets are served by an international distribution network of more than 50 partners.

### **Quantel Medical**

Business contact:

Jan-Philippe Heydel: [Jan-Philippe.Heydel@quantel-medical.fr](mailto:Jan-Philippe.Heydel@quantel-medical.fr)

Press contact:

Stephanie Belot: [Stephanie.Belot@quantel-medical.fr](mailto:Stephanie.Belot@quantel-medical.fr) - [www.quantel-medical.com](http://www.quantel-medical.com)